Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study.
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms UC CIMZIA
- 07 Jun 2017 Biomarkers information updated
- 10 May 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2017.
- 10 May 2016 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2017.